Tirzepatide Grey Market Risks and Quality

Tirzepatide is a prescription-only medicine in every jurisdiction we cover: the US (branded as Mounjaro and Zepbound), the EU and EEA (Mounjaro, centrally authorised by the EMA in September 2022^[1]), and the UK (MHRA-licensed). Despite this, a grey market has developed around the drug. Unlicensed compounders, online sellers, and outright counterfeiters have filled a demand gap created by high retail prices and extended supply shortages. This article covers what regulators and lab testing have found in those products, what a certificate of analysis can and cannot tell you, and why self-sourcing tirzepatide carries risks that are difficult to measure.

Counterfeit Mounjaro in the supply chain

Counterfeit tirzepatide pens have entered both grey-market channels and, in some cases, the regulated supply chain itself. In February 2026 the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a safety alert after fake Mounjaro 15 mg KwikPens were dispensed by a pharmacy in Birmingham. The fakes carried batch number D873576, which belongs to a genuine 7.5 mg product. Testing confirmed the pens contained tirzepatide but were manufactured under unknown conditions, raising sterility concerns^[2].

In October 2025, MHRA's Criminal Enforcement Unit raided a warehouse in Northampton and seized over 2,000 filled injection pens containing tirzepatide and retatrutide, along with tens of thousands of empty pens, raw chemical ingredients, and manufacturing equipment. Authorities described it as the largest single seizure of trafficked weight-loss medicines worldwide^[3]. Retatrutide is not approved anywhere globally and remains in clinical trials, so the seized material was entirely unlicensed.

Eli Lilly has stated that it does not supply compounders with tirzepatide, and the company has found contaminated and counterfeit products labelled as Mounjaro or Zepbound. Some contained bacterial contamination, high impurity levels, unusual colours (pink instead of the expected colourless solution), or entirely different chemical structures^[9].

Compounded tirzepatide after the shortage ended

During the FDA-declared tirzepatide shortage (which began in 2022), compounding pharmacies were permitted to prepare versions of the drug under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. On 2 October 2024 the FDA determined that the shortage had been resolved. That triggered enforcement deadlines: state-licensed pharmacies (503A) had until 18 February 2025 to stop compounding tirzepatide, and outsourcing facilities (503B) had until 19 March 2025. After those dates, compounding tirzepatide without a valid legal basis became a federal violation.

Not all compounders stopped. In April 2026 the FDA issued a warning letter to ProRx LLC for producing tirzepatide without eligibility, citing unsanitary conditions, labelling failures, and inadequate adverse-event reporting. The agency stated it found no clinical need for outsourcing facilities to compound these drugs from bulk substances^[5]. Other compounders, including BPI Labs and Medisource, ceased production in response to tightening regulations.

A 2026 study in the Annals of Pharmacotherapy examined 33 compounded semaglutide and tirzepatide products. About 48% combined the active ingredient with add-ons such as cyanocobalamin, glycine, niacinamide, or ondansetron. The authors found minimal justification for these additions. Only 18% of products reported beyond-use dating, and only 28% documented storage conditions^[6].

Recalls and adverse events

The FDA has recalled multiple batches of compounded tirzepatide for sterility and potency failures. In July 2025, Aequita Pharmacy in Washington recalled over 2,000 multi-dose vials of tirzepatide/niacinamide injections due to lack of processing controls. The same year, Thrive Health and Wellness in Colorado recalled 1,484 pre-filled syringes of tirzepatide formulations for lack of assurance of sterility^[7].

A retrospective analysis of the FDA's Adverse Event Reporting System (FAERS) identified 65,974 tirzepatide reports between 2022 and 2025. The single most common event category was dosing errors, accounting for over 30,000 reports. Incorrect dose administration alone surged from 1,715 reports in 2022 to 15,887 in 2024^[8]. The authors attributed most errors to the once-weekly schedule and mandatory dose-escalation protocols rather than device design. However, compounded vials, which require manual dose measurement, add a separate layer of error risk on top of this.

As of late 2024, the FDA had received over 900 adverse-event reports associated with compounded semaglutide and tirzepatide combined, including 17 deaths^[9]. Some hospitalisations resulted from patients self-administering five to twenty times the intended dose because of confusion between milligrams, millilitres, and "units" on non-standardised vial labels.

What a COA can and cannot tell you

A certificate of analysis (COA) from a grey-market vendor typically reports peptide purity by HPLC and molecular identity by mass spectrometry. That tells you whether the target molecule was present in the tested sample. It does not tell you whether the specific vial you received matches the tested batch, whether the product has degraded in transit or storage, or whether the COA itself is genuine. Grey-market COAs are produced by the manufacturer or by a lab paid by the manufacturer, with no independent audit trail.

For tirzepatide specifically, a standard COA also cannot confirm sterility, endotoxin levels, or the presence of add-on ingredients that some compounders include without disclosing. The same identity and purity limitations apply to other grey-market peptides, including BPC-157 and semaglutide.

Harm reduction if you are considering grey-market tirzepatide

This section is not an endorsement. Tirzepatide is a prescription medicine for a reason: it requires dose titration, monitoring for gastrointestinal and metabolic side effects, and clinical judgement about whether it is appropriate for a given patient. If you are weighing the decision regardless, these are the questions worth asking.

Is the product coming from a licensed pharmacy you can verify independently? Does the COA come from a named, independent third-party lab (not the compounder's own facility)? Does the label specify concentration, storage conditions, and an expiry date? Has anyone sent a sample from the same batch to a second lab for independent verification? If the answer to most of these is "no" or "I don't know," the product carries risks you cannot measure.

What we do not know

No published study has systematically tested a panel of grey-market tirzepatide vials for identity, purity, contamination, and sterility. The FAERS data captures voluntarily reported events, and the database likely undercounts the true volume of adverse events from compounded products^[8]. We do not know how many people are self-administering grey-market tirzepatide without incident, and we do not know the real-world rate of serious adverse events outside the reporting systems.

If you are considering tirzepatide for weight management or type-2 diabetes, that conversation belongs with a clinician who knows your medical history. For a full overview of tirzepatide's clinical evidence and regulatory status, see our tirzepatide peptide page.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide is a prescription-only medicine in every jurisdiction we cover. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.